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Abstract 
 
Aims.  RhoB plays a key role in the pathogenesis of hypoxia-induced pulmonary hypertension. 
Farnesylated RhoB promotes growth responses in cancer cells and we investigated whether inhibition of 
protein farnesylation will have a protective effect.  
Methods and Results.  The analysis of lung tissues from rodent models and pulmonary hypertensive 
patients showed increased levels of protein farnesylation.  Oral farnesyltransferase inhibitor tipifarnib 
prevented development of hypoxia-induced pulmonary hypertension in mice. Tipifarnib reduced 
hypoxia-induced vascular cell proliferation, increased endothelium-dependent vasodilatation and 
reduced vasoconstriction of intrapulmonary arteries without affecting cell viability. Protective effects of 
tipifarnib were associated with inhibition of Ras and RhoB, actin depolymerisation and increased eNOS 
expression in vitro and in vivo.  Farnesylated-only RhoB (F-RhoB) increased proliferative responses in 
cultured pulmonary vascular cells, mimicking the effects of hypoxia, while both geranylgeranylated-
only RhoB (GG-RhoB) and tipifarnib had an inhibitory effect. Label-free proteomics linked F-RhoB 
with cell survival, activation of cell cycle and mitochondrial biogenesis. Hypoxia increased and 
tipifarnib reduced the levels of F-RhoB-regulated proteins in the lung, reinforcing the importance of 
RhoB as a signalling mediator. Unlike simvastatin, tipifarnib did not increase the expression levels of 
Rho proteins. 
Conclusions. Our study demonstrates the importance of protein farnesylation in pulmonary vascular 
remodeling and provides a rationale for selective targeting of this pathway in pulmonary hypertension. 
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Introduction 
Pulmonary hypertension (PH) is characterised by increased pulmonary vascular resistance due to 
pulmonary vasoconstriction and vascular remodeling and hypoxia is one of the major underlying causes 
of the disease.
1
 
 
Ras family of proteins, including Rho GTPases, are key regulators of actin dynamics and cell 
proliferation.
2
 Activation of RhoA contributes to sustained hypoxic pulmonary vasoconstriction and 
pulmonary vascular remodeling in hypoxia-induced PH and in other forms of PH.
3
 We have recently 
shown that RhoB, a protein homologous to RhoA is required for hypoxia-induced HIF-1α stabilization, 
vascular cell proliferation and migration in vitro.
4
 Coordinated activation of RhoA and RhoB maximizes 
contractile responses of VSMCs to hypoxia: RhoB induces actin polymerization via its interaction with 
mammalian homolog of Drosophila diaphanous (mDia), while RhoA and its effector, Rho kinase, 
increase phosphorylation of myosin light chain on Ser19, thereby facilitating the formation of contractile 
actomyosin (stress) fibres.
4
  RhoB gene deletion attenuates PH in mice, indicating a unique role of this 
protein in the disease pathology.
4
  
 
RhoB is distinguished from other Rho proteins by being either farnesylated (F-RhoB) or 
geranylgeranylated (GG-RhoB) while other Rho proteins are only geranylgeranylated.
5
 Lipid 
modification (isoprenylation) of Ras proteins is important for their biological activity. Attachment of the 
20-carbon chain (geranylgeranylation) or 15-carbon chain (farnesylation) at the C-terminal CAAX motif 
enhances their binding to the cell membrane, important step for the interaction with signaling effectors. 
Isoprenylation is carried out by enzymes geranylgeranyl-transferases (GGTase-1 and GGTase-2) or 
farnesyl-transferase (FTase).  Biological activity of RhoB is thought to be determined by its prenylation 
status.
6
 In cancer cells, geranylgeranylation of RhoB induces apoptosis and is required for RhoB 
degradation 
7
, while farnesylation of RhoB is associated with pro-proliferative effects.
6
  
Protein prenylation can be inhibited by statins, which limit biosynthesis of the isoprenoid precursor, 
mevalonate.  In spite of the successful outcomes in preclinical studies, statins are not effective in the 
treatment of human PH.
8
 This disappointing clinical outcome may result from the fact that statins do not 
completely inhibit protein farnesylation at safe therapeutic doses,
9
, suggesting that proteins that require 
farnesylation for their activity, like RhoB or Ras, may remain functional.  
 
We hypothesized that selective inhibition of protein farnesylation will have a protective effect in 
pulmonary hypertension. FTase inhibitors (FTIs) have undergone extensive clinical testing in various 
hematologic malignancies and progeria.
10,11
 Recent Phase II clinical trials demonstrated high 
effectiveness of lonafarnib in reducing viral infection and treatment of chronic hepatitis delta.
12
 Orally 
bioavailable, non-peptidomimetic FTI tipifarnib has shown promising effects in clinical trials for the 
treatment of leukemia
13
 and cancer.
14
 The suitability of FTIs in treatment of PH has not been 
investigated, though an isolated case study has demonstrated a substantial improvement of pulmonary 
artery systolic pressure in pulmonary hypertensive leukaemic patient treated with tipifarnib.
15
  
 
Our study addresses for the first time the effect of farnesyltransferase inhibition in prevention of chronic 
hypoxia-induced pulmonary hypertension and in the regulation of pulmonary endothelial function in 
vitro and in vivo.  
 
 
Methods 
An expanded Methods section is provided in the online Data Supplement. 
Chronic hypoxia-induced pulmonary hypertension. 
Normoxia and chronic hypoxia studies in vivo. All studies were conducted in accordance with UK Home 
Office Animals (Scientific Procedures) Act 1986 and institutional guidelines with the Imperial College 
ethics review board approval. 12-15 weeks old C57BL male mice (20 g; Charles River, Margate, UK) 
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were either housed in normal air or were placed in a normobaric hypoxic chamber (FIO2 10%) for 2 
weeks (n= 6-8/group). Mice were treated twice daily by oral gavage with either vehicle (2% 
carboxymethylcellulose in PBS) or tipifarnib (100 mg/kg/body weight).Treatments started one day prior 
hypoxia exposure. Development of PH was verified as described previously.
4
 At 2 weeks, the animals 
were weighed and anesthetized (Hypnorm 0.25 mL/kg; Midazolam 25 mg/kg IP), and right ventricular 
systolic pressure (RVSP) was measured in a closed chest via direct cardiac puncture in the 
spontaneously breathing, anesthetized animal. A 27G needle, connected to a blood pressure transducer 
(MLT0670, ADInstruments) and to PowerLab Data Acquisition system (ADInstruments), was 
introduced within the second intercostal space proximal to the sternal angle with an inclination of 45 
degrees clockwise. All data were then analysed using LabChart 7 software. The animals were then 
euthanized, the hearts were removed, and the individual ventricular chambers were weighed. Right 
ventricular hypertrophy was assessed as the ratio of right ventricle/ left ventricle + septum. The right 
lungs were snap-frozen in liquid nitrogen and stored at −80°C for biochemical measurements. The left 
lungs were fixed by inflation with 10% formalin, embedded in paraffin, and sectioned for histology. 
Transverse lung sections were stained with van Gieson’s elastic method or smooth muscle-actin 
antibody (Sigma) and counterstained with Gill’s No. 2 haematoxylin (Sigma, GHS216). Vascular 
muscularisation was defined as the proportion of vessels (<50 µm diameter) with immunoreactivity for 
smooth muscle actin (as evidence for muscularization) over the total number of vessels stained with 
elastin. 
 
PAH lung sections for immunofluorescent staining of farnesylated proteins.  
Archived lung tissue sections from patients undergoing transplantation for PAH and relevant control 
material was obtained from the Papworth Hospital Cambridge and Hammersmith Hospital London 
tissue banks with local ethics committee approval (REC reference number 2001/6003 for Hammersmith 
Hospital and 08/H0304/56+5 for Papworth Hospital) and informed written consent. The investigation 
conformed to the principles outlined in the Declaration of Helsinki. 
 
Immunostaining of lung sections.  
Lung sections were immunostained using a rabbit anti-farnesyl-proteins antibody (Milipore, AB4073) 
and a mouse anti-alpha-smooth muscle actin antibody (Dako, M0851) and fluorescently-labelled 
secondary antibodies. Images were taken under the confocal laser scanning fluorescence microscope 
(Leica TCS SP5) and analysed with Image J. 
 
Cell culture and treatments 
Human pulmonary artery endothelial cells (HPAEC; Promocell, C-12241, lot 7121003.5 and 4091902) 
and smooth muscle cells (HPASMCs; Promocell, C-12521, lot  9033101.6) were cultured, as described 
in 
4
 . The cells were used between passages 3-6. The cells were kept under normoxia or were exposed to 
hypoxia (2% O2) for 2-72 hours. In experiments involving a short-term (2 hours) exposure to hypoxia, 
tipifarnib (Selleckchem) was added to the cells 1 hour before the hypoxic exposure at 0.1µmol/L. In 
experiments involving a more prolonged exposure to hypoxia (24 – 72 hours), tipifarnib was added to 
the cells at the start of hypoxic exposure.
4
  
 
Intracellular calcium levels. HPAECs grown in 96-well optical bottom plates (Costar, 3603) were left 
untreated or were treated with 0.1µmol/L tipifarnib for 24 hours. Calcium flux was induced by thrombin 
(Sigma, T4648, 1U/mL) or ionomycin (Sigma, I3909, 1µmol/L) for 3 minutes. Intracellular calcium 
levels were studied with Fluo4 NW Calcium Assay kit (Invitrogen, F36206), according to the 
manufacturer’s protocol. Images of cells were taken under the confocal laser scanning fluorescence 
microscope (Leica TCS SP5) and the intensity of Fluo4 fluorescence (excitation 494 nm and emission 
516 nm) was measured with Image J. 
 
Isometric wire myography 
Myography was performed on pulmonary artery segments isolated from control C57BL6 mice or mice 
exposed to chronic hypoxia. Intralobar pulmonary artery was removed, dissected free of fat and 
connective tissues and the vessel segments placed in Mulvany wire myographs to measure contraction 
and relaxation responses. Throughout the experiment, tissues were immersed in physiological salt 
solution (PSS, NaCl 1.18 x 10
-1
 mol/L, KCl 4.7 x 10
-3
 M, MgSO4 1.17 x 10
-3
 mol/L, CaCl2 2.5 x 10
-3
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mol/L, KH2PO4 1.0 x 10
-3
 mol/L, EDTA 2.7 x 10
-5
 mol/L, and glucose 5.5 x 10
-3
 mol/L) at 36 °C, 
bubbled with 95% O2 and 5% CO2. The tension of the vessel was normalised to a tension equivalent to 
that generated at 90% of the diameter of the vessel at 100 mmHg. Changes in arterial tone were recorded 
via a PowerLab/800 recording unit (ADI instruments Pty Ltd., Australia), and analysed using Chart 6.0 
acquisition system (ADI instruments). Arteries were exposed to three challenges of high potassium 
solution (KPSS; some composition as PSS except that NaCl is replaced with KCl 1.24 x 10
-1
 mol/L) 
followed by a washout period of 10 min. Concentration response curves to 9,11-dideoxy-11α,9α 
epoxymethanoprostaglandin F2α (U46619; 10-9-3.10-7 mol/L) and phenylephrine (10-8-10-4 mol/L) were 
performed on each of the vessels. Dilatory response curves were recorded in pulmonary arteries pre-
contracted with an EC80 concentration of U46619, and vasodilator responses to either acetylcholine (10
-
8
-10
-4
 mol/L) or SNP response curve (10
-8–3.10-5 mol/L) were assessed. Force was recorded via a 
PowerLab/800 (AD Instruments Ltd., UK) and analysed using Chart 6.0 acquisition system (AD 
Instruments Ltd., UK). 
 
Proliferation, metabolic activity and apoptosis assays 
HPAECs and HPASMCs proliferation was evaluated using bromodeoxyuridine (BrdU) assay 
(Millipore), while cell viability and caspase activation were assessed using the kit ApoTox-Glo™ 
(Promega). Metabolic activity (NADH/NADPH levels) was measured in CellTiter 96® Aqueous One 
Solution Cell Proliferation Assay System (Promega, USA). The levels of cleaved caspase 3 in tipifarnib-
treated cells and mouse lungs were analysed by western blotting. Apoptotic DNA fragmentation was 
studied with TACS 2 TdT-DAB In Situ Apoptosis Detection Kit (Trevigen, 4810-30K).  
 
Endothelial Permeability. 
Endothelial permeability was measured in Transwell assay.
4
 
 
Rho GTPases Protein Expression and Activity 
Active (GTP-bound) RhoA, RhoB levels were measured in pulldown assays.
4
 Ras GTP-binding was 
studied with Raf-1–GST fusion construct encoding residues 51–131 of the human Raf-1 RBD 
(generously provided by Johannes L. Bos, Molecular Cancer Research, UMC Utrecht, The 
Netherlands).
16
 
 
Activity measurement of farnesyltransferase and geranylgeranyltransferase 
The protocol was adapted from Berndt et al. 
17
, replacing the [H
3
]FPP/[H
3
]GGPP and peptide substrates 
with non-radioactive FPP/GGPP and fluorophore-conjugated peptides. The prenylation substrates, 
nitrobenzofurazan (NBD)-GCVLS (FTase substrate) and NBD-GCVLL (GGTase-1 substrate) become 
strongly fluorescent upon prenylation.  
 
Globular / Filamentous actin quantification 
The ratio of globular (G) actin to filamentous (F) actin was measured with G/ F-actin In vivo Assay Kit 
(Cytoskeleton, Denver, CO, USA).  
 
Real-time RT-PCR analysis 
First-strand cDNAs were synthesized directly from HPAECs using the Superscript Cells Direct cDNA 
Synthesis Kit (Invitrogen) according to the manufacturer’s protocol. Polymerase chain reactions (PCRs) 
were performed using specific primer pairs for NOS3 (Hs01274659_m1) and GAPDH 
(Hs02758991_g1), from Taqman®.  
 
RhoB mutant overexpression 
Overexpression of AdGFP (adenoviral control), farnesylated-only RhoB (F-RhoB) and 
geranylgeranylated-only RhoB (GG-RhoB), was induced by adenoviral gene transfer.
4
 The last four C-
terminal aminoacids of the F-RhoB were CLVS. In GG-RhoB, 16 terminal residues of RhoB were 
replaced C by 13 C terminus of RhoA, with the last four residues CLVL.
18
 CMV3/zeo HA-F-RhoB and 
CMV/zeo HA-GG-RhoB were a kind gift of Professor George Prendergast, Lancaster Avenue, 
Wynnewood, PA). The adenoviral vectors for RhoB mutant overexpression were from Welgen, 
Worcester, MA USA). 
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Label- free quantitative proteomics 
Cells lysates were separated by SDS-PAGE. After in-gel digestion of the separated proteins, tryptic 
peptides were analyzed by LC-MS/MS. Data analysis was performed by applying various criteria to 
ensure certainty in the assignment of protein identifications and to select those that were differentially 
expressed. Functional associations of the identified proteins were analysed with STRING (Search Tool 
for the Retrieval of Interacting Genes/Proteins 10.0) database (http://string-db.org/) and Ingenuity 
Pathway Analysis version 01-07. 
 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 6 Software. Comparisons were carried out 
with unpaired Student’s t-test or ANOVA with Dunnett’s, Tukey or Bonferroni post-hoc tests, as 
appropriate. Statistical significance was accepted for P<0.05. Data are expressed as means±SEM. 
 
 
Results 
Tipifarnib prevents development of chronic hypoxia-induced pulmonary hypertension in mice 
Mice exposed to chronic hypoxia for 2 weeks developed pulmonary hypertension, characterised by an 
increase in the right ventricular systolic pressure (RVSP), right ventricular hypertrophy (RVH) and 
muscularization of small (<50µm diameter) intrapulmonary arteries (Figure 1a-d). Pulmonary vascular 
muscularization was accompanied by an increase in the protein expression of cell proliferation marker 
PCNA in the lung (Supplementary Figure S1).  
Following oral treatment with tipifarnib (100 mg/kg, twice daily), the mice appeared healthy and no 
treatment-related mortality or significant weight loss were noted during the experiment (Supplementary 
Figure S2). Twice- daily oral administration of tipifarnib at 300 mg/kg was shown to alleviate symptoms 
of PH in a leukaemic patient
15
. However, in mice a lower dose of 100 mg/kg twice daily efficiently 
inhibited growth of H-ras transfected  tumors and therefore this dose was chosen in our investigation
19
. 
Tipifarnib prevented the hypoxia-induced increase in RVSP and significantly reduced RVH and 
pulmonary arterial muscularization in hypoxic mice (Figure 1A-D). The effects of tipifarnib were 
accompanied by a significant reduction in the lung expression of PCNA (Supplementary Figure S1). 
 
Tipifarnib reduces protein farnesylation in the lung.  
Hypoxia increased protein farnesylation in the lung, while tipifarnib had an inhibitory effect (Figure 2 
A, B). The effectiveness of the selected dose of tipifarnib was documented by an increase in the levels of 
unprenylated farnesylation marker protein HDJ2 and reduction in the levels of farnesylated RhoB and 
H-Ras in mouse lungs (Figure 2 C, D and Supplementary Figure S3). The selectiveness of the antibody 
used to visualise farnesylated proteins was verified by western blotting (Supplementary Figure S4). To 
further investigate, whether protein farnesylation increases in PH lung, we examined the levels of 
protein farnesylation in rat lungs with monocrotaline (MCT)-induced PH and lungs of human patients 
with severe PAH. Consistent with the observations in the remodelled mouse lungs, MCT rat and human 
PAH lungs showed increased levels of protein farnesylation, compared with healthy controls (1.6- and 
1.5-fold increase respectively, p<0.05) (Supplementary Figures S5 and S6). 
Hypoxic mouse lungs did not show changes in protein levels of FTase, GGTase or the activity of FTase, 
but the activity of GGTase was significantly reduced compared with normoxic controls (Figure 2E and 
Supplementary Figure S7). Reduction in GGTase activity may potentially enhance protein farnesylation 
by increasing bioavailability of isoprenoid intermediates and/or protein substrates utilised by FTase.
20
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Tipifarnib increases endothelium-dependent relaxation of pulmonary arteries.  
We evaluated the effect of tipifarnib on vascular reactivity of mouse intrapulmonary arteries.  Acute (2h) 
ex vivo treatment with tipifarnib decreased contraction of intrapulmonary arteries to high K
+
 and 
prostaglandin H2 analog, U46619 and increased acetylcholine-mediated vasorelaxation (Figure 3 A-C). 
Tipifarnib-induced increase in vasorelaxation was prevented by NOS inhibitor L-NAME, indicative of 
increased endothelial NOS signaling (Supplementary Figure S8). Relaxation to the NO donor SNP was 
also enhanced in the presence of the inhibitor (Supplementary Figure S9).  
Chronic hypoxia induced pulmonary arteries hypercontractility in response to high K
+
 and U46619 and 
decreased vasorelaxation to acetylcholine (Figure 3A-C). Chronic (2 weeks) treatment with tipifarnib 
reduced K
+
- and U46619-induced contractility and significantly improved acetylcholine-induced 
vasorelaxation of intrapulmonary arteries from hypoxic lungs (Figure 3A-C) but had little effect on 
relaxation to SNP (Supplementary Figure S9). 24 hour treatment with tipifarnib did not significantly 
affect intracellular calcium levels in the untreated or thrombin-treated HPAECs (Supplementary Figure 
S10). 
 
Tipifarnib reduces hypoxia-induced HPAEC and HPASMC proliferation and inhibits the 
activities of H-Ras and small GTPases in vitro and in vivo. 
Tipifarnib inhibited hypoxia-induced HPAEC and HPASMC proliferation (Figure 4A, B), without 
affecting cell viability or apoptosis in vitro or in vivo (Supplementary Figure S11).  The drug also 
prevented hypoxia-induced activation of Ras and Rho proteins in the lung, without altering protein 
expression (Figure 4 C-E and Supplementary Figure S12). In cultured cells, reduction in RhoB activity 
was noted at 2 hours and RhoA and Ras activity at 24 hours of treatment with tipifarnib (Supplementary 
Figure S13).  
Tipifarnib reduces F-actin levels and stabilises eNOS mRNA in pulmonary endothelial and 
smooth muscle cells.  
Rho-induced actin polymerization reduces the stability of eNOS mRNA and decreases NO production.
21
 
To better understand the mechanism of vasorelaxing actions of tipifarnib, we studied the effect of the 
drug on actin polymerization in cultured HPAECs and HPASMCs.  
 
Tipifarnib reduced the levels of polymerised actin (F-actin) in hypoxic HPAECs and HPASMCs and 
prevented the localization of phosphorylated myosin light chain (p-MLC) to stress fibres, indicative of 
reduced actomyosin contractility (Figure 5A, B and Supplementary Figure S14 A, B).  
Increase in the levels of unpolymerised, globular (G)-actin correlated with increased gene and protein 
expression of eNOS in tipifarnib-treated HPAECs and mouse lungs (Figure 5A-G). 
 
Farnesylated RhoB induces an activated, pro-proliferative cell phenotype. 
To evaluate the effect of changes in RhoB prenylation on pulmonary endothelial cell phenotype, we 
overexpressed farnesylated-only RhoB (F-RhoB) or geranylgeranylated-only RhoB (GG-RhoB) in 
HPAECs. Both mutants induced stress fibre formation and cell rounding in HPAECs within 10-24 hours 
of overexpression, with F-RhoB  having a more pronounced effect (Figure 6).  Differential effects of the 
two mutants were more clearly seen at earlier timepoints of mutant overexpression (6 hours), when F-
RhoB, but not GG-RhoB significantly increased endothelial permeability (Supplementary Figure S15). 
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F-RhoB also increased metabolic/proliferative activity in HPAECs and its effects were inhibited by 
tipifarnib (Figure 6C).  
Label-free proteomics analysis showed significantly increased expression of 60 proteins in cells 
overexpressing F-RhoB and 16 proteins in cells overexpressing GG-RhoB (Figure 6B and 
Supplementary Table S1). Pathway analysis linked F-RhoB with activation of cell growth and 
biogenesis, while GG-RhoB with cell cycle inhibition and protein ubiquitination (Supplementary Tables 
S1 and S2). Consistent with the postulated role of RhoB, we observed a significant increase in the levels 
of F-RhoB-regulated proteins, such as afadin (cell survival, PDGF and Akt signalling, angiogenesis)
22,
 
23
, heat shock 70 proteins
24
 and peroxisome proliferator-activated receptor gamma coactivator- related 
1(PPRC1; transcription factor of mitochondrial biogenesis)
25
, in hypoxic mouse lungs, while treatment 
with tipifarnib had an inhibitory effect (Figure 7).   
Consistent with the results of proteomic profiling, F-RhoB also increased BrdU incorporation in 
HPAECs and platelet-derived growth factor-BB (PDGF-BB) -stimulated HPASMCs while GG-RhoB 
had an inhibitory effect (Supplementary Figure S16).   
 
Differential effect of Tipifarnib and simvastatin on protein expression of small GTPases  
Statin treatment carries health risks associated with increased accumulation of unprenylated Ras proteins 
contributing to their sudden activation upon drug withdrawal.
26
 To highlight potential benefits of FTI-
based therapy, we compared changes in protein expressions of RhoA, RhoB and Ras in cells treated with 
tipifarnib and simvastatin.  Tipifarnib did not significantly alter protein expressions of Ras, RhoA or 
RhoB, in contrast to simvastatin, which markedly upregulated the expressions of all studied proteins 
(Supplementary Figure S17 A-C). This differential effect may result from the fact that FTIs selectively 
inhibit protein farnesylation, preserving, or even increasing protein geranylgeranylation, important for 
the ubiquitination and subsequent degradation of Ras proteins. In support of this hypothesis, we 
observed that co-incubation of tipifarnib-treated cells with GGTase-1 inhibitor, GGTI-298 substantially 
elevated protein expressions of RhoA and H-Ras to the levels induced by simvastatin (Supplementary 
Figure S17).  
 
Discussion 
In this study, we show that oral administration of non-peptidomimetic farnesyltransferase inhibitor 
tipifarnib to chronically hypoxic mice, significantly improves eNOS-dependent vasodilatation, reduces 
pulmonary vascular remodeling and prevents hypoxia-induced right heart hypertrophy. FTIs have shown 
promise in treatment of vascular pathologies associated with atherosclerosis
27
, progeria
28
 and systemic 
hypertension
29
 and here we document potential role of FTIs in treatment of pulmonary hypertension. 
 
Reduction in pulmonary vascular remodeling by tipifarnib may be attributed, at least in part, to the 
inhibition of expression and activity of Ras proteins (Figure 8).  Inhibition of Ras farnesylation inhibits 
neointimal thickening of coronary artery,
30
 reduces PDGF-induced VSMC proliferation and inhibits the 
actions of Ras effectors such as endothelin-1 (ET-1), or TGF-β.31  RhoB is a downstream effector of Ras 
and  regulates intracellular trafficking of EGF and PDGF receptors and kinases src and Akt, enhancing 
cell proliferation and survival.
32,33,34
 Several human and animal studies have also established the 
importance of RhoA and its downstream mediator, ROCK, in pulmonary arterial contractility and 
remodelling.
34
 Interestingly, tipifarnib reduced the activity of RhoA which, unlike Ras or RhoB, can 
only be geranylgeranylated. This effect may result from increased NO/cGMP/PKG-mediated 
phosphorylation of RhoA, known to promote arterial vasodilation.
35
 
 
Tipifarnib decreased pulmonary arterial vasoconstriction to high K
+
 and U46619 in a NOS-independent 
manner.  Considering that RhoB has a short half-life (~2 hours for RhoB compared to ~24-31 hours for 
Ras and RhoA) and that the acute treatment with tipifarnib decreased RhoB activity without affecting 
RhoA or Ras, this response can be attributed to the inhibition of RhoB.   
Inhibition of Rho signaling can also account for NOS-dependent increase in vasorelaxation seen in 
pulmonary arteries treated with tipifarnib. Rho/Rho kinase inhibitors increase the levels of 
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unpolymerised, globular (G)-actin, known to stimulate eNOS  expression either by binding to the 
enhancer region of eNOS promoter
36
 and/or by stabilising eNOS mRNA.
21
 In addition, G-actin can bind 
to eNOS residues 326-333 can shift its enzymatic activity from superoxide formation toward NO 
production,
37
 or stimulate eNOS activity via PI3-kinase/Akt-mediated phosphorylation.
38
 Further, 
depolymerization of actin has been shown to activate eNOS by reducing  stiffness of the cell cortex.
39
  
 
Accordingly, we observed that increased eNOS gene and protein expression co-incided with actin 
depolymerisation and reduced activities of RhoA and RhoB. Tipifarnib improved acetylcholine-induced 
vasorelaxation of hypoxic intrapulmonary arteries and increased eNOS protein expression in the lung. 
Interestingly, total RhoB knockout in mice did not affect pulmonary vasoreactivity, possibly as a result 
of a compensatory increase in RhoA expression 
4
, not seen in tipifarnib-treated lungs. Tipifarnib did not 
alter intracellular Ca
2+
 levels in the untreated or thrombin-treated cells, suggesting that modulation of 
Rho rather than Ca
2+
-calmodulin signalling 
40
 contributed to the vasorelaxing effects of the drug. 
 
Tipifarnib is the most clinically relevant agent available, with proven on-target effects in vivo.
41
 Clinical 
trials showed that the drug is relatively well tolerated, and does not significantly affect cardiovascular 
function.
42,43
 It is important to note, that the outcomes of anti-farnesylation therapies may vary, 
depending on disease mechanisms, experimental design, dose and route of drug administration, FTI 
specificity and the mode of action. In this study, tipifarnib reduced pulmonary arterial remodeling and 
improved endothelium-dependent vasorelaxation in hypoxic mice in a mechanism involving inhibition 
of Ras and Rho signaling. However, in a mouse model of progeria, tipifarnib prevented loss of arterial 
media by reducing farnesylation of progerin. Permanent farnesylation of progerin is thought to 
destabilise nuclear lamina in arterial VSMCs, making them susceptible to shear stress-induced damage. 
28
 In another study, one-daily intravenous administration of structurally unrelated peptidomimetic 
farnesyltranefease inhibitor, FTI-276 improved cardiac remodeling but failed to significantly alter 
endothelium-dependent vasorelaxation in spontaneously hypertensive rats.
29
  
 
Data from our and other laboratories suggest that the equilibrium between protein farnesylation and 
geranylgeranylation is important in control of growth responses in the cardiovascular system.
44,45
 In 
particular, prenylation status of RhoB is likely to play a role. FTI-induced gain-of-function increase in 
GG-RhoB  inhibits cancer cell proliferation
18
 and we have shown that GG-RhoB inhibits PDGF-induced 
HPASMC proliferation. In contrast, F-RhoB stimulates cell proliferation and increases expression of 
proteins important for cell survival, cell division, mitochondrial biogenesis and energy metabolism.  
Increased expression of F-RhoB-regulated proteins was also observed in PH mouse lungs, providing an 
argument for the role of RhoB farnesylation in lung responses to chronic hypoxia. Mechanisms inducing 
differential prenylation of proteins such as RhoB and affecting the activity of prenyltransferases are 
poorly understood.
46
 It is possible that hypoxia-induced increase in protein farnesylation results from 
selective inhibition of GGTase activit 
20
 or changes in expression of regulatory proteins.
46
 
 
Identification of other FTI targets important in the pathogenesis of PAH, will require further studies. 
Database searches for potential farnesylation targets (proteins terminating in CAAX motifs) identified 
dozens of proteins, some of which can potentially be implicated in the pathogenesis of PH. These 
include several bone morphogenetic proteins, transforming growth factor-β precursors, serine/threonine 
kinase-11 and inositol-1,4,5-trisphosphate 5-phosphatases (I and IV), all of which are proteins with 
potential roles in the growth regulation.
47
 
 
Our study highlights potential therapeutic benefits of selective inhibition of protein farnesylation, as 
opposed to the use of general prenylation inhibitors, such as statins. Statins are not effective in inhibiting 
protein farnesylation at safe therapeutic doses
9
 and induce the accumulation of unprenylated, immature 
forms of Ras proteins that maintain partial function.
7
 In contrast to simvastatin, tipifarnib did not 
increase protein expressions of Ras or Rho in vitro or in vivo, possibly as a result of alternative 
geranylgeranylation, targeting Rho proteins for proteasomal  degradation.
7
 These effects were reversed 
by GGTi-995, supporting the argument that by shifting the balance towards protein geranylgeranylation, 
FTIs may exert better control over disease-related increases in Rho proteins expression and activity than 
statins.  
CVR-2016-1011 
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Preliminary analysis of lung tissues from MCT rats and PAH patients showed increased protein 
farnesylation in the remodelled vessels and the surrounding tissues, suggesting a potential broader 
significance of this pathway in the pathogenesis of the disease. Such an assumption may appear too far-
fetched, considering the complexity of vascular pathology in PAH.
48
  However,  protein farnesylation 
increases in numerous other proliferative and inflammatory disorders
46,49 
 and is likely to affect the 
function of a variety cell types in addition to the cell types studied here. Hypoxia alone or in 
combination with other vascular stresses contributes to PAH pathology
1
 and RhoB can be activated by 
numerous other factors implicated in the pathogenesis of PAH, including tyrosine kinases TGF-β/bone 
morphogenetic protein/smad pathway and growth factors, fibroblast growth factor, epidermal growth 
factor, and PDGF. 
3,33
 Further studies will need to address the role of FTIs in non-hypoxic models of PH 
and provide a detailed comparative analysis of the effects of FTIs and statins. Potential pro-apoptotic 
effects of FTIs will also need to be considered. Tipifarnib can induce apoptosis in malignant cells
50
 and 
the results of studies examining the effects of farnesyltransferase inhibition in normal adult tissues are 
unclear.
51
 
 
To summarise, this study provides a molecular rationale for further exploring the family of 
farnesyltransferase inhibitors in treatment of pulmonary hypertension. 
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Figure legends 
Figure1. Tipifarnib attenuates development of chronic hypoxia-induced pulmonary hypertension. 
(A) right ventricular hypertrophy (RVH), (B) Right ventricular systolic pressure (RVSP), (C, D) vessel 
muscularization in the lungs of normoxic and chronically hypoxic mice treated with vehicle or tipifarnib 
(100 mg/kg). In (D) top panel shows smooth muscle actin (SMA) staining in lung sections from hypoxic 
control lungs and bottom panel shows SMA staining in lungs from tipifarnib-treated hypoxic mice. 
Magnified boxed areas illustrate changes in muscularization of small intrapulmonary arteries. In (A-C) 
values are means±SEM of n=6; 
*
p<0.05, 
**
p<0.01, 
***
p<0.001 vs normoxic control; 
##
p<0.01, 
###
p<0.001 
vs hypoxic control. 1-way ANOVA with Tukey post-test. 
Figure 2. Tipifarnib reduces protein farnesylation in lungs of hypoxic PH mice. (A) 
Immunofluorescent images of farnesylated proteins and α-smooth muscle actin in the lungs of normoxic 
mice and vehicle- and tipifarnib-treated hypoxic mice, as indicated.  Bar=10µm. (B) Changes in protein 
farnesylation in mouse lungs. Values are mean fluorescence intensities ±SEM of n=6/group; *p<0.05. 1-
way ANOVA with Tukey post-test. (C, D) Representative western blots showing tipifarnib-induced 
accumulation of unprenylated (np; upper band) form of farnesylation marker protein, HDJ2 and 
reduction in the levels of farnesylated RhoB and H-Ras in the mouse lung. (E) FTase activity and 
GGTase activity in the lungs of normoxic (clear boxes) and chronically hypoxic mice (black boxes). 
Each data point represents a mean± SD of n=5-6. The Vmax and Km of the curves were compared using 
the Michaelis–Menten equation fitted to data points. **p< 0.005, comparison with normoxic controls, 
for both Vmax and Km. 
Figure 3: Tipifarnib increases endothelium-dependent relaxation of pulmonary arteries. In (A-C) 
graphs on the left show reactivity of intrapulmonary arteries pretreated for 2 hours with 0.1 μmol/L 
tipifarnib (Acute treatment), while graphs on the right show reactivity of intrapulmonary arteries isolated 
from normoxic, hypoxic and hypoxic tipifarnib-treated mice (Chronic treatment). (A) Contraction to 
high potassium solution; (B) contraction to U44162; (C) relaxant response to acetylcholine. Values are 
means ± SEM of n=4 for acute treatment and n=8-12 for chronic treatment. 0% relaxation corresponding 
to the level of precontraction induced by 3x10
-6
 mol/L U44162. Statistical significance was determined 
using a (A) unpaired t-test or (B, C) a two-way ANOVA with repeated measures and a Bonferroni post-
hoc test. *p<0.05, **p<0.01, ***p<0.001 vs control; #p<0.05, ###p<0.001 vs hypoxic control. 
 
 
Figure 4. Tipifarnib reduces cell proliferation and small GTPases activity. Proliferation of (A) 
HPAECs or (B) HPASMCs cultured in media containing 1% FBS in normoxia or in hypoxia with or 
without tipifarnib for 72 hours (0.1 µmol/L; BrdU assay). Cells in positive controls were stimulated with 
10% FBS. Activities of (C) RhoA, (D) RhoB and (E) Ras were assessed in lungs of mice exposed to 
normoxia or chronic hypoxia and treated with either vehicle or tipifarnib, as indicated. -actin was used 
as a normalization control. Data represent mean fold- change ±SEM of n=5. 
*
p<0.05, 
**
p<0.01 vs 
normoxic control; 
#
p<0.05, 
##
p<0.01 vs hypoxic control. 1-way ANOVA with Tukey post-test. 
Figure 5: Tipifarnib depolymerises actin and increases eNOS expression in HPAECs and mouse 
lungs. (A) Graph and (B) representative western blot show changes in globular/filamentous (G/F) actin 
ratio in HPAECs treated with tipifarnib (0.1µmol/L) for for 2-24 hours, as indicated. n=7-8. (C) eNOS 
mRNA and (D, E) eNOS protein expression in cells  stimulated with tipifarnib; n=5-6. (F, G) eNOS 
protein expression in the lungs of mice exposed to normoxia or chronic hypoxia and treated with either 
vehicle or tipifarnib, n=6. Results are expressed as fold- change of controls; Data represent mean±SEM 
*p<0.05 vs normoxic control. 1-way ANOVA with Tukey post-test. 
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Figure 6: Farnesylated RhoB induces stress fibre formation and increases  metabolic activity in 
HPAECs.  (A) The effect of 24 hour-overexpression of AdF-RhoB and AdGG-RhoB on the endothelial 
actin cytoskeleton. The RhoB mutants were HA-tagged and co-expressed with GFP and AdGFP was 
used as adenoviral control (Adcontrol). In merged images F-actin is red, HA is blue and GFP is green. 
Bar=10µm.  Western blot shows equal RhoB expression levels in cells infected with Ad F-RhoB and Ad 
GG-RhoB. (B) Volcano plot illustrates differences in protein expression profile in cells overexpressing 
GG-RhoB or F-RhoB. Dots in the upper right hand and the left hand corner represent significantly 
altered expression, with the enlarged red dots marking proteins that affect cell metabolic 
activity/biosynthesis. All up- or down- regulated proteins are listed in the Supplementary Table S1 and 
those that are involved in metabolic activity/biosynthesis are indicated. The broken lines indicate 
thresholds of 1.5-fold-change and p-value 0.05; n=5. (C) Changes in the metabolic activity in cells 
overexpressing AdGFP, AdF-RhoB and AdGG-RhoB and treated with tipifarnib, as indicated.  Values 
are means ± SEM of n=5.
 **
p<0.001 vs control, 
# 
p<0.05 comparison, as indicated. 1-way ANOVA with 
Tukey post-test. 
Figure 7. Farnesylated RhoB increases expression of proteins regulating cell survival, activation of 
cell cycle and mitochondrial biogenesis. (A) Fold-change in protein levels of afadin, PPRC1 and 
HSPA6 in HPAECs overexpressing F-RhoB. Bars are means±SEM, *p<0.05; **p<0.01, comparison 
with adenoviral controls (Adcontrol); n=6. Representative western blots are shown beside the graph. (B) 
Fold-change in protein levels of afadin, PPRC1 and HSPA1 in normoxic mouse lungs (Normoxia), 
hypoxic mouse lungs (Hypoxia+Vehicle) and lungs of hypoxic mice treated with Tipifarnib 
(Hypoxia+Tipifarnib).  HSPA6 is not expressed in rodents and therefore the expression of HSPA1, 
belonging to the same HSP70 family of proteins and regulated by F-RhoB, was analysed.  Values are 
means ± SEM of n=6 and the broken line indicates control level. *p<0.05; **p<0.01, comparison with 
normoxic controls. 1-way ANOVA with Tukey post-test. Representative western blots are shown beside 
the graph.  
Figure 8. A schematic diagram of the proposed signaling pathway. FTase: farnesyltransferase; 
ROCK: Rho kinase; mDia: mammalian homolog of Drosophila diaphanous. 
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Tipifarnib prevents development of hypoxia-induced pulmonary hypertension. 
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SUPPLEMENTAL MATERIAL 
 
 
Monocrotaline-induced PH rat lung  
All studies were conducted in accordance with UK Home Office Animals (Scientific Procedures) Act 
1986 and institutional guidelines with the Imperial College ethics review board approval. Lung sections 
of healthy and MCT adult male Sprague- Dawley rats (weight, 200–250 g; from Charles River, UK) 
were obtained from paraffin-embedded lungs from our previous study.
1
 Specifically, rats were injected 
with monocrotaline (MCT, 60 mg/kg; Sigma-Aldrich) subcutaneously and 4 weeks later mean 
pulmonary arterial pressure (mPAP) was measured by catheterization via right jugular vein (mPAP: 
MCT 45.1 ±9.1 mmHg vs control 18.5±3.6 mmHg, P<0.01), and the ratio of RV to LV plus the septum 
mass (RV/LV+septum) was used as an index of RV hypertrophy (MCT 0.46±0.11 vs control 0.24±0.01, 
P<0.001). Left lungs were inflated and fixed with 10% formalin for histology examination. 
 
 
Cell culture. Human pulmonary artery endothelial cells (HPAECs) were grown on fibronectin-coated 
(bovine fibronectin, Sigma-Aldrich Company Ltd. Gillingham, Dorset, UK) plastic ware in Human 
Endothelial Cell Growth Medium 2 supplemented with 2% foetal calf serum and EGF (5 µg/L), basic 
FGF (10 µg/L), IGF (20 µg/L), VEGF (0.5 µg/L), ascorbic acid (1mg/L), heparin (22.5 mg/L) and 
hydrocortisone (0.5 mg/L). Human pulmonary artery smooth muscle (HPASMCs) were grown in the 
Human Smooth Muscle Cell Growth Medium 2 supplemented with 5% Foetal calf serum, EGF (0.5 
µg/L) and FGF (2 µg/L). The cells were cultured under normal oxygen tension (20% O2, 5% CO2) or 
exposed to hypoxia (2% O2, 5% CO2, 92% N2) for 1- 48 hr. The cells and culture media were from 
PromoCell (Heidelberg, Germany). In experiments involving a short-term (2 hours) exposure to 
hypoxia, tipifarnib (Selleckchem) was added to the cells 1 hour before the hypoxic exposure at 0.1 µM.
2
 
In experiments involving a more prolonged exposure to hypoxia (24 – 72 hours), tipifarnib was added to 
the cells at the start of hypoxic exposure. Following the treatment, the cells were used for studies of Rho 
GTPases expression, activity, F-actin organisation, cell proliferation and viability. 
 
 
Endothelial Permeability. 
Confluent HPAECs growing in Transwell filters (0.4µm pore size, VWR) were left untreated or were 
infected with AdGFP (Adcontrol), AdF-RhoB or AdGG-RhoB. 18 hours post-infection, fluorescent 
dextran (FITC-dextran, MW 40 kDa, Sigma; 0.5 g/L) was added to the top chamber of Transwell dishes 
for 1 hour and changes in endothelial barrier function were studied by the measurement of passage of 
FITC-dextran through the endothelial cell layer. 
  
Immunofluorescence and confocal microscopy. The cells cultured on plastic coverslips (Nunc, cat no 
174950) were fixed with 4% formaldehyde solution in PBS for 10 minutes at room temperature and 
permeabilised for 3 minutes with 0.1% Triton X-100. The cells were incubated in 2% bovine serum 
albumin (BSA, Sigma) in PBS for 45 minutes to block non-specific antibody binding and then incubated 
with mouse monoclonal anti-p-Ser20 MLC antibody (Sigma, 10 mg/L), washed 2x in PBS and 
incubated with FITC-labelled goat anti-mouse antibody (Jackson ImmunoResearch Laboratories, 115-
095-062; 10 µg/ml) and 1mg/L of TRITC-phalloidin (Sigma) to stain actin filaments. Coverslips were 
washed 3x in PBS and mounted in Vectashield mountant containing nuclear stain DAPI.  
To stain farnesylated proteins,  dewaxed and rehydrated lung sections were subjected to heat-induced 
antigen retrieval in 10 mmol/L sodium citrate (pH 6.0) and 0.05% Tween 20, at 80°C for 20 minutes, 
and immunostained using the avidin-biotin-peroxidase complex (ABC Elite, Vector Laboratories) 
method and 3,3'-diaminobenzidine as a substrate. Sections were incubated with a rabbit anti-farnesyl-
proteins antibody (Milipore, AB4073, 5µg/mL) and a mouse anti-alpha-smooth muscle actin antibody 
(Dako, M0851, 5µg/ml). Secondary antibodies used were Cy-5 anti-rabbit (Jackson ImmunoResearch 
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Laboratories, 711-175-152, 5µg/ml) and TRITC anti-mouse secondary antibodies (Jackson 
ImmunoResearch Laboratories, 115-025-146, 5µg/ml). Sections incubated with purified non-immune 
rabbit IgG were used as staining controls. Slides were mounted in Vectashield mountant containing 
nuclear stain DAPI.  
 
Images on cells were taken under the confocal laser scanning fluorescence microscope (Leica TCS SP5). 
 
Western blot analysis. Following electrophoresis and protein transfer, the membranes were probed with 
the following primary antibodies: mouse monoclonal anti-RhoA (Santa Cruz Biotechnology; sc-418), 
rabbit anti-RhoB (Santa Cruz Biotechnology; sc-180), rabbit anti-PCNA (Santa Cruz Biotechnology; 
sc9857); rabbit polyclonal anti-HA (Santa Cruz Biotechnology; sc-805); mouse monoclonal anti-β-actin 
(Sigma; A2228); rabbit anti-eNOS (Millipore; 07-520), mouse anti-H-Ras (Millipore; MAB-3291), 
mouse anti- Ras (Millipore; 05-1072), rabbit anti- farnesyl-proteins (Millipore; AB4073), mouse anti-
vinculin (Abcam; ab18058) and rabbit anti-HDJ2 (Abcam; ab3089), rabbit monoclonal anti-cleaved 
caspase-3 (Cell Signaling; 9664), rabbit monoclonal anti-Afadin (Thermoscientific, A7L9H48), rabbit 
anti-PPRC1 (Atlas Antibodies, HPA038511), rabbit anti-HSPA6 (Santa Cruz Biotechnology, sc-
292204) and rabbit anti-HSPA1 (Santa Cruz Biotechnology, sc-133679). Secondary antibodies: goat 
anti-rabbit HRP-labelled (Sigma; AG154) and goat anti-mouse HRP-labelled antibody (Dako; 2016-07). 
Primary antibodies were used at 1mg/L and secondary antibodies at dilution 0.2 mg/L. The relative 
intensity of the immunoreactive bands was determined by densitometry using Image J software 
(Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, 
http://imagej.nih.gov/ij/, 1997-2011). The results were normalised to -actin or vinculin levels and 
expressed as fold- change over control. Untreated control samples were included in every experiment 
and all experiments were repeated at least 3 times (n≥3). 
 
Immunoprecipitation of RhoB. 
Confluent HPAECs grown in 3cm petri dishes were infected with adenoviruses to induce overexpression 
of F-RhoB or GG-RhoB. 24 hours post-infection, the cells were lysed in 1 mL lysis buffer containing 
0.5% NP-40 (ThermoFisher Scientific), 10 mmol/L Tris-HCl pH 7.6, 150 mmol/L sodium chloride, 30 
mmol/L sodium pyrophosphate, 5mmol/L EDTA with the protease and protein phosphatase inhibitor 
mix (ThermoFisher Scientific; 88266 and 78420). 50 µL of total cell lysates were reserved for 
subsequent analysis by electrophoresis and western blotting. The remaining cell lysates were pre-cleared 
by incubation with 30 µL of Protein G Sepharose (Sigma; P3296) for 1 hour. Sepharose beads were 
collected by centrifugation and the supernatants were incubated overnight with 5 µL of a rabbit anti-
RhoB (Santa Cruz Biotechnology; sc-180) at 4°C. Then, 30 µL of Protein G Sepharose were added to 
the lysates for 1 hour and the beads were spun down in a benchtop centrifuge at 13 000 rpm for 3 
minutes. The beads were washed 3 x in PBS, re-suspended in sample buffer, boiled and resolved by 
electrophoresis, followed by western blotting. 
 
Semi-quantitative Reverse Transcriptase Polymerase Chain Reaction (RTPCR). To characterise changes 
in eNOS mRNA expression in HPAECs, total RNA was isolated using the RNeasy mini kit (Qiagen, 
Netherlands). Prior to cDNA synthesis, the RNA was treated with DNase I (Invitrogen) to remove any 
residual genomic DNA. 1 μg of total RNA was used for cDNA synthesis. First-strand cDNA synthesis 
was performed using Superscript II reverse transcriptase (Invitrogen). RT–PCR was performed with 
isoform-specific primers for NOS3 (Hs01274659_m1) and GAPDH (Hs02758991_g1), from Taqman®.  
Adenoviral overexpression of RhoB prenylation mutants. Overexpression of farnesylated-only (F-RhoB) 
and geranylgeranylated-only (GG-RhoB) RhoB was induced by adenoviral gene transfer. CMV3/zeo 
HA-F-RhoB and CMV/zeo HA-GG-RhoB were a kind gift of Professor George Prendergast, Lancaster 
Avenue, Wynnewood, PA). The last four C-terminal amino acids of the F-RhoB were CLVS, while in 
GG-RhoB, 16 terminal residues of RhoB were replaced C by 13 C terminus of RhoA, with the last four 
residues CLVL.
3
 Adenoviral constructs for the farnesylated-RhoB (HA-F-RhoB; Ad-teto-RhoB-mut-F-
GFP), geranylgeranylated-RhoB (HA-GG-RhoB; Ad-teto-RhoA/B-GG-GFP) as well as adenoviral 
control (Ad-GFP) were made using Ad5 E1E3 backbone vector (Welgen Worcester, MA USA). 
Briefly, the cDNA of RhoB-F and RhoB-GG  was inserted into pENTCMV3-GFP vector pre-digested 
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with Hind3/Xba1 respectively. The positive clones were screened with EcoR1 and sequenced. The 
pENT-RhoBmut-GG-GFP, pENT-RhoBmut-NG-GFP and pENT-RhoBmut-FF-GFP were treated with 
LR Clonase II enzyme (Invitrogen) and ligated to a pAd-REP plasmid that contains the remaining 
adenovirus genome. The recombination products were transformed into E. coli. After incubation 
overnight, the positive clones were selected, and cosmid DNA were purified. The purified cosmid DNA 
(2 mg) was digested with Pac1 and then transfected into 293 cells with Lipofectamine 2000 according to 
manufacturer’s instructions. The adenovirus plaques were seen 7 days after transfection. All 
adenoviruses were amplified in HEK293 cells and subsequently purified on 2 sequential caesium 
chloride gradients and then passed through PD10 columns (GE Healthcare) to reduce the salt 
concentration. The titre of Ad-HA-RhoB-F and Ad-HA-RhoB-GG was 2 x 10
11
 pfu (plaque forming 
units)/ml and 4x x 10
11
 pfu/ml respectively. Mutant protein expression was confirmed by 
immunofluorescence and Western blotting 
Adenoviral infection was carried out at MOI (multiplicity of infection) 1:100. 
 
BrdU incorporation measurement. Proliferation HPAECs and HPASMCs grown in 96-well plates was 
evaluated using bromodeoxyuridine (BrdU) assay (Millipore), according to the manufacturer’s 
recommendations.  
HPAECs grown in full EGM-2 medium were infected with adenoviruses to overexpress AdGFP, AdF-
RhoB or AdGG-RhoB. BrDU assay was carried out 18 hours post-infection. HPASMCs were infected 
with adenoviruses and pre-starved for 6 hours in culture medium containing 0.1% FCS before the 
addition of PDGF-BB (eBioscience, 20 µg/L) and BrdU. Following an overnight incubation, BrdU 
proliferation assay (Milipore) was carried out. As the overexpression of RhoB prenylation mutants 
induced actomyosin contractility and cell rounding, the 450nm absorbance value was normalised to the 
number of cells in untreated controls. 
Fluorescent staining of BrdU-positive nuclei was carried out on cells fixed in 4% formaldehyde in PBS, 
according to the BrdU Labeling and Detection Protocol recommended by ThermoFisher Scientific 
(https://www.thermofisher.com/uk/en/home/references/protocols/cell-and-tissue-
analysis/protocols/brdu-labeling-and-detection-protocol.html). The cells were incubated with primary 
mouse monoclonal Pierce anti-BrdU antibody (Life Technologies, MA1-82088, 10µg/mL), washed and 
incubated with a secondary FITC-labelled goat anti-mouse antibody (Jackson ImmunoResearch 
Laboratories, 115-095-062;   10µg/mL) together with 1mg/L of TRITC-phalloidin (Sigma) to stain actin. 
Coverslips were washed 3x in PBS and mounted in Vectashield mountant containing nuclear stain 
DAPI.                                                                    
 
Label Free Proteomics. Cell lysates from HPAECs overexpressing RhoB mutants were prepared in 9M 
Urea. Protein content was estimated using the bicinchoninic acid method (Thermo Fischer Scientific, 
Cramlington, UK) with bovine albumin as standard. SDS-PAGE was performed using 10% NuPAGE 
Novex bis-tris gels and reagents (Invitrogen Ltd., Paisley, UK). Samples (n=5 per group) were reduced 
by addition of 50 mmol/L L-dithiothreitol prior to heating at 100°C for 2 min and then 
carbamidomethylated by addition of 200 mmol/L iodoacetamide in the dark for 30 min. Gels were 
stained with InstantBlue® and each sample-containing lane cut into a series of regions (R1-R14) based 
on the position of molecular weight (MW) markers (Spectra™, Multicolar Broad Range, Life 
Technologies) and the distribution of proteins observed in the gel. Each gel piece was then digested with 
trypsin, peptides extracted, and dried as described previously.
4
 Lyophilised samples were reconstituted 
in 30 µL of 0.1% TFA and 10 µL of the solution was injected onto a C18 trap-column (ProteCol, 0.3 x 
10 mm, 300Å; SGE Analytical Science Pty Ltd. Victoria, Australia) followed by reverse phase 
separation on a C18 column (PicoFrit, 75µm ID × 10 cm ProteoPrep column, New Objective Inc., 
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Massachussetts, USA) using Agilent 1200 LC series (Agilent Technologies UK Ltd., Berkshire, UK) as 
previously described.
4
 MS data was assessed on the basis of ion intensity of peptide ions with coincident 
LC retention time and m/z values as previously described.
4
 Protein identification was based on the 
presence of ≥2 unique peptides. Protein abundance values were calculated on the basis of the ion 
intensities of the component peptides. These data were displayed as an intensity map by Progenesis LC-
MS software (Nonlinear Dynamics, Newcastle upon Tyne, UK). As the criterion of protein identification 
applied was based on detection ≥2 unique peptides, values for every peptide in all samples resulted; i.e. 
no data was excluded. Consequently, statistical comparisons based on parametric statistics were applied 
for each protein in all samples. Differentially expressed proteins were determined by identifying proteins 
with at least 2 unique peptides, ≥1.5 fold difference and P<0.05 (Student’s t-test).  
Functional associations of the identified proteins were analysed with STRING (Search Tool for the 
Retrieval of Interacting Genes/Proteins version 10.0) database and Ingenuity Pathway Analysis version 
01-07. 
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Supplemental Data 
 
Figure S1 
 
 
 
Figure S1. Tipifarnib reduces PCNA expression in lungs of chronically hypoxic mice.  
Graph and representative western blot show PCNA protein expression in the lungs of normoxic and 
chronically hypoxic mice treated with vehicle or tipifarnib (100 mg/kg). Data represent mean±SEM of 
n=5. **p<0.01 vs normoxic control; #p<0.05 vs hypoxic control. 1-way ANOVA with Tukey post-test. 
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Figure S2 
 
 
 
 
Figure S2. Tipifarnib does not significantly affect mouse weight. Mice were exposed to 2-week 
hypoxia and were given oral  tipifarnib 100mg/kg twice daily (treatment group) or vehicle (hypoxic 
control group); n=8.
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Figure S3 
 
 
 
Figure S3. Tipifarnib increases the levels of unprenylated HDJ2 in mouse lungs. Mice were treated 
twice daily by oral gavage with either vehicle (2% carboxymethylcellulose in PBS) or tipifarnib (100 
mg/kg/body weight).Treatments started one day prior hypoxia exposure. The effectiveness of tipifarnib 
in inhibition of protein farnesylation was confirmed by accumulation of nonprenylated form of HDJ2 
(upper band of HDJ2 protein) in mouse lung lysates analysed by western blotting. Representative 
example of western blot is shown in Figure 2D; ***p<0.001, comparison with controls, unpaired t-test; 
n=4.
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Figure S4 
 
 
 
 
Figure S4. Detection of F-RhoB and GG-RhoB with rabbit anti-farnesyl-proteins antibody 
(Milipore, AB4073). HPAECs overexpressing F-RhoB or GG-RhoB were lysed and RhoB was 
immunoprecipitated with rabbit anti-RhoB antibody. Total cell lysates and sepharose beads with 
immunoprecipitated RhoB were resolved by electrophoresis followed by western blotting. The blots 
were then probed with a rabbit anti-farnesylated proteins antibody, anti-RhoB and anti-β-actin 
antibodies.  
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Figure S5. 
 
Figure S5. Increased protein farnesylation in MCT rat lung. (A) Representative immunofluorescent 
images showing cell nuclei (blue),  farnesylated proteins (green) and α-smooth muscle actin (red) in 
MCT rat lung and control, healthy lung, as indicated. In the negative control, the tissues were incubated 
with the secondary antibodies only. All images were taken with the same settings of laser power and 
gain. Bar=10µm. (B) Change in the levels of farnesylated proteins in MCT lung. Fluorescence intensity 
was measured in 3 random fields of 4 healthy control lungs and 4 MCT lungs and results are expressed 
as % of healthy control values ±SEM.  *p<0.05, unpaired t-test. 
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Figure S6 
 
Figure S6. Elevated protein farnesylation in PAH lungs. (A) Representative immunofluorescent 
images showing cell nuclei (blue), farnesylated proteins (green) and α-smooth muscle actin (red) in PAH 
lung and control, healthy lung tissue, as indicated. In the negative control, the tissues were incubated 
with the secondary antibody only. All images were taken with the same settings of laser power and gain. 
Bar=10µm. (B) Increased levels of farnesylated proteins in PAH lung. Fluorescence intensity was 
measured in 3 random fields of 4 healthy control lungs and 8 PAH lung tissues and results are expressed 
as % of healthy control values ±SEM.  *p<0.05, unpaired t-test. 
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 Figure S7 
 
 
 
Figure S7. Hypoxia does not affect farnesyltransferase and geranylgeranyltransferase protein 
expression in vitro or in vivo. Protein expression of farnesyltransferase subunit beta (FTβ) in (A) 
HPAECs exposed to hypoxia for 1-24 hours and (B) in lungs of mice exposed to chronic hypoxia for 2 
weeks. (C) and (D) show protein expression of geranylgeranyltransferase subunit beta (GGTβ) in 
HPAECs and hypoxic lung tissues, as indicated. Representative western blots are shown above the 
graphs. Densitometric analysis of western blots; β-actin expression was used as sample loading control. 
Results are expressed as mean fold- change over control ±SEM. In (A, C) n=5-6 and in (B, D) n=4.  
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Figure S8 
 
 
 
 
Figure S8. L-NAME prevents tipifarnib-induced increase in vasorelaxation. (A) Contractile 
response to phenylephrine, (B) relaxant response to acetylcholine and (C) relaxant response to SNP, 
were assessed in mouse intrapulmonary arteries pretreated with 0.1 μmol/L tipifarnib for 2 hours and 
100 μmol/L L-NAME for 30 minutes prior to the start of the experiment. Data represent mean ± SEM of 
n=4, 0% relaxation corresponding to the level of precontraction induced by 3x10
-8
 M phenylephrine. 
Statistical significance was determined using a (A-C) two-way ANOVA with repeated measures and a 
Bonferroni post-hoc test. **p<0.01 vs control; ##p<0.01 vs tipifarnib. 
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Figure S9. 
 
 
 
Figure S9. The effect of tipifarnib on relaxant response to SNP. Relaxant responses of 
intrapulmonary arteries (A) pretreated for 2 hours with 0.1 μmol/L tipifarnib (Acute treatment) or (B) 
isolated from normoxic, hypoxic and hypoxic tipifarnib-treated mice (Chronic treatment). Data represent 
mean ± SEM of n=4 for acute treatment and n=8-12 for chronic treatment, 0% relaxation corresponding 
to the level of precontraction induced by 3x10
-6
 mol/L U44162. *p<0.05, comparison with control. 
Statistical significance was determined using a two-way ANOVA with repeated measures and a 
Bonferroni post-hoc test. 
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Figure S10. 
 
Figure S10.  Tipifarnib does not change intracellular calcium levels in HPAECs. HPAECs were left 
untreated or were treated with 0.1µmol/L tipifarnib for 24 hours. Calcium flux was induced by thrombin 
(1U/mL) or ionomycin (1µmol/L) for 3 minutes. Intracellular calcium levels were studied with Fluo4 
NW Calcium Assay kit (Invitrogen, F36206), according to the manufacturer’s protocol. Images of cells 
were taken under the confocal laser scanning fluorescence microscope (Leica TCS SP5) and the 
intensity of Fluo4 fluorescence (excitation 494 nm and emission 516 nm) was measured with Image J. 
**p<0.01, ***p<0.0001, comparison with untreated controls, 1-way ANOVA, Dunnett’s post-test; n=5.
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Figure S11. 
 
Figure S11. Tipifarnib does not affect cell viability or apoptosis. (A) Cell viability and (B) caspase 
activation were measured in multiplexed assay ApoTox-Glo™ assay in HPAECs stimulated with 
tipifarnib (0.1 µmol/L) and exposed to hypoxia for 24 hours. Results are expressed as mean fold- change 
over control±SEM, n=4. Graph in (C) and corresponding representative western blots in (D) show 
changes in protein levels of cleaved caspase 3 in HPAECs treated with tipifarnib (0.1 µmol/L), lungs of 
hypoxic mice (Hypoxia+Vehicle) and lungs of hypoxic mice treated with tipifarnib 
(Hypoxia+Tipifarnib). In (C) cleaved caspase expression is shown as fold-change over control untreated 
HPAECs or control normoxic lungs, as appropriate ± SEM; n=6. Broken line indicates control level. 
Cell lysate of menadione-treated HPAECs (50µmol/L, 6hours) was used as a positive control. (E) 
Immunohistochemical analysis of apoptotic DNA fragmentation in mouse lungs with TACS 2 TdT DAB 
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in situ Apoptosis Detection kit (Trevigen). Apoptotic nuclei are brown with Methyl Green counterstain. 
In positive control TACS-Nuclease was added to the labelling mix to generate DNA breaks. Negative 
control did not have dTdT enzyme in the labelling mix. Bar=50µm. Images are representative of n=4. 
 
 
Figure S12. 
 
 
 
Figure S12. Tipifarnib reduces protein expression of Ras and RhoB in lungs of hypoxic mice. (A) 
Ras, (B) H-Ras, (C) RhoB and (D) RhoA protein expression levels were studied in the lungs of 
normoxic mice or hypoxic mice treated with vehicle or tipifarnib.  Data represent mean±SEM of n=5-6. 
*p<0.05, vs normoxic control.1-way ANOVA with Dunnett’s post-test. 
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Figure S13. 
 
 
 
Figure S13. Farnesyltransferase inhibition reduces the activities of RhoA, RhoB and Ras in 
HPAECs. Activities of (A) RhoA, (B) RhoB and (C) Ras were assessed in HPAECs treated with 
tipifarnib for 2 hours or 24 hours, as indicated.  β-actin was used as a normalization control. Results are 
expressed as fold-change of controls. Data represent mean±SEM of n=4-7. *p<0.05, **p<0.01 
***p<0.001 vs control. 1-way ANOVA with Tukey post-test. 
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Figure S14 
 
 
Figure S14. Tipifanib prevents hypoxia-induced increase in F-actin levels in HPAECs and 
HPASMCs.  (A) HPAECs or (B) HPASMCs were left untreated or were treated with 0.1 µmol/L 
tipifarnib and exposed to hypoxia for 2 hours. F-actin was stained with TRITC-phalloidin and the 
intensity of fluorescence was measured in confocal images with Image J. Representative images of cells 
are shown above the graphs. Values are means±SEM of n=5-6. *p<0.05; **p<0.001, comparison with 
normoxic controls. 1-way ANOVA with Tukey post-test. (c) Tipifarnib inhibits the localization of 
phosphorylated MLC to stress fibres in hypoxic HPASMCs; confocal microscopy. The arrowhead points 
to p-Ser19 MLC co-localising with F-actin fibres in hypoxic HPASMCs. In merged images, F-actin is 
red, p-Ser19 MLC is green and nuclei are blue. Bar=10µm. 
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Figure S15. 
 
 
 
Figure S15. Farnesylated RhoB increases endothelial permeability in HPAECs. HPAECs were 
infected with AdGFP (Adcontrol), F-RhoB or GG-RhoB. 6 hours post-infection, endothelial 
permeability was measured as passage of fluorescent dextran across HPAEC monolayer; fold-change  of 
controls. Values are means±SEM of n=6. **p<0.01; comparison with adenoviral controls. 1-way 
ANOVA with Tukey post-test. 
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Figure S16. 
 
 
Figure S16. Farnesylated RhoB stimulates BrdU incorporation in HPAECs and HPASMCs. (A) BrDU 
incorporation in HPAECs overexpressing AdGFP (Adcontrol), AdF-RhoB or AdGG-RhoB for 18 hours; 
(B) BrDU incorporation in HPASMCs overexpressing AdGFP or RhoB mutants and treated with 20 
ng/mL of PDGF-BB, as indicated. HPASMCs were pre-starved for 6 hours in culture medium 
containing 0.1% FCS, infected with adenoviruses and incubated with PDGF for 18 hours before BrdU 
proliferation assay (Milipore). The 450 nm absorbance value was normalised to the number of cells in 
untreated controls. Values are means±SEM of n=5-6. **P<0.01, comparison with untreated controls 
(HPAECs) or with adenoviral controls (HPASMCs); ***P<0.001, comparison with adenoviral controls; 
#
P<0.05, comparison with Adcontrols (HPAECs) or PDGF-treated Adcontrols (HPASMCs), as 
appropriate. 1-way ANOVA with Tukey post-test. (C) Fluorescent staining of BrdU incorporation in 
untreated HPAECs or HPAECs overexpressing AdF-RhoB or AdGG-RhoB, as indicated. All nuclei are 
labelled with DAPI (blue), BrdU-incorporating nuclei are green (arrowheads) and F-actin is red. 
Bar=30µm.  
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Figure S17. 
 
 
Figure S17: Differential effect of simvastatin and tipifarnib on protein expression of Ras and Rho 
GTPases in HPAECs. (A) RhoA, (B) RhoB and (C) H-Ras protein expression was studied in HPAECs 
incubated with simvastatin (10 µmol/L), tipifarnib (0.1 µmol/L), GGTi-995 (5µmol/L) or a combination 
of tipifarnib with GGTi-995 for 24 hours, as indicated. Results are expressed as fold change over 
control. Data represent mean ± SEM of n=4. 
*
p<0.05, 
**
p<0.01, 
***
p<0.001 vs control;
 ##
p<0.01, 
###
p<0.001 vs simvastatin-treated cells; 
$
p<0.05 vs tipifarnib-treated cells. 1-way ANOVA with Tukey 
post-test. Corresponding representative western blots are shown below the graphs.
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Table S1: Proteomic analysis of differentially expressed proteins in HPAECs overexpressing RhoB 
mutants: proteins upregulated in HPAECs overexpressing F-RhoB or GG-RhoB. (a) lists proteins 
increased in GG-RhoB-overexpressing HPAECs and (b) lists proteins increased in F-RhoB-
overexpressing HPAECs. Only proteins with fold-increase >1.5 and p value <0.05, were listed.  (+) or (-
) indicate higher or lower protein levels in FF samples compared to GG. * Proteins involved in the 
regulation of cell metabolism identified with STRING 
 
(a)                       Proteins increased in GG-RhoB-overexpressing HPAECs 
Protein Ratio p value Adj. 
p 
value 
Protein 
accession 
number 
Gene 
symbol 
Protein Jumonji* -2.64 1.58E-02 0.16 NP_004964 JARID2 
Protein misato homolog 1 -2.43 4.19E-02 0.27 NP_060586 MSTO1 
182 kDa tankyrase-1-binding protein -2.27 1.76E-03 0.09 NP_203754 TAB182 
Protein disulfide-isomerase A6* -2.17 2.75E-03 0.07 NP_005733 PDIA6 
Disks large homolog 5*  -2.09 9.97E-03 0.14 NP_004738 DLG5 
Coiled-coil domain-containing 
protein 57  
-1.92 3.04E-02 0.25 NP_932348 CCDC57 
Kinesin-like protein KIF14* -1.84 3.17E-02 0.25 NP_055690 KIF14 
Proteasome subunit beta type-3* -1.80 4.59E-02 0.28 NP_002786 PSMB3 
Chromodomain-helicase-DNA-
binding protein 7* 
-1.68 3.68E-02 0.26 NP_060250 CHD7 
Beta-enolase -1.67 3.37E-02 0.25 NP_001967 ENO3 
26S protease regulatory subunit 7* -1.65 4.99E-02 0.29 NP_002794 PSMC2 
Helicase SRCAP* -1.64 3.81E-02 0.26 NP_006653 SRCAP 
Spectrin alpha chain -1.62 2.72E-02 0.23 NP_003117 SPTA1 
Hsc70-interacting protein* -1.54 4.09E-02 0.27 NP_003923 ST13 
Importin-4 -1.54 5.19E-02 0.29 NP_078934 IPO4 
Meiotic nuclear division protein 1 
homolog 
-1.54 4.94E-02 0.29 NP_115493 MND1 
  
(b)                          Proteins increased in F-RhoB-overexpressing HPAECs 
RANBP2-like and GRIP domain 
containing 6 
8.60 3.95E-02 0.27 NP_005045 RGPD6 
Small G protein signaling modulator 
2* 
5.80 1.38E-02 0.14 NP_055668 SGSM2 
CUB and sushi domain-containing 
protein 2 
3.40 5.83E-04 0.03 NP_443128 CSMD2 
3-hydroxyacyl-CoA dehydrogenase 
type-2 
3.18 6.10E-04 0.03 NP_004484 HSD17B10 
Epidermal growth factor receptor 
substrate 15-like 1 
2.65 2.73E-02 0.29 NP_067058 EPS15L1 
Caspase recruitment domain-
containing protein 14* 
2.63 2.50E-02 0.22 NP_077015 CARD14 
synaptojanin-dependent RNA 
helicase DDX1 
2.59 1.92E-02 0.19 NP_004930 DDX1 
Heat shock 70 kDa protein 1-like 2.54 1.35E-03 0.04 NP_005518 HSPA1L 
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E3 ubiquitin-protein ligase RNF213 2.44 3.74E-02 0.32 NP_00124300
0 
RNF213 
Plastin-3 2.42 1.63E-03 0.07 NP_005023 PLS3 
ATP-binding cassette sub-family F 
member 2 isoform* 
2.42 1.47E-04 0.04 NP_005683.2 
 
ABCF2 
RNA polymerase II transcription 
factor SIII  
2.35 1.42E-03 0.04 NP_057511 TCEB3B 
Serine/threonine-protein kinase 
DCLK2 
2.32 3.06E-02 0.24 NP_00103535
0 
DCLK2 
Gamma-tubulin complex component 
6 
2.31 4.80E-02 0.36 NP_065194 TUBGCP6 
Plastin-2* 2.23 2.37E-02 0.28 NP_002289 LCP1 
Poly [ADP-ribose] polymerase 14 2.20 8.96E-03 0.12 NP_060024 PARP14 
Unconventional myosin-VI* 2.15 1.48E-02 0.16 NP_004990 MYO6 
Transketolase 2.14 7.59E-03 0.07 NP_001055 TKT 
Transmembrane 9 superfamily 
member 3 
2.14 4.75E-02 0.28 NP_064508 TM9SF3 
Protein CASC5* 2.11 3.86E-02 0.26 NP_733468 CASC5 
EF-hand domain-containing family 
member B 
2.07 4.10E-02 0.37 NP_653316 EFHB 
serine/threonine-protein phosphatase 
2A 65 kDa  
2.04 8.65E-03 0.16 NP_859050 PPP2R1B 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase*  
2.04 1.14E-02 0.11 NP_002941 RPN1 
Asparagine--tRNA ligase, 
cytoplasmic 
2.03 7.13E-03 0.15 NP_004530 NARS 
Sperm flagellar protein 2* 2.01 3.55E-02 0.32 NP_079143 SPEF2 
Plectin* 2.00 1.32E-02 0.15 NP_958781 PLEC 
Cytoskeleton-associated protein 4* 1.98 1.58E-02 0.09 NP_006816 CKAP4 
Rhodopsin kinase* 1.97 1.74E-03 0.05 NP_002920 GRK1 
WD repeat-containing protein 1 1.96 1.58E-02 0.11 NP_059830 WDR1 
Heat shock 70 kDa protein 6 1.96 1.09E-02 0.048 NP_002146 HSPA6 
Very long-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
1.94 1.27E-02 0.11 NP_00102903
1 
ACADVL 
60S acidic ribosomal protein P2* 1.93 4.24E-02 0.26 NP_000995 RPLP2 
Dihydropyrimidinase-related protein 
2* 
1.91 1.76E-02 0.11 NP_00118422
2 
DPYSL2 
Eukaryotic translation initiation 
factor 3* 
1.87 2.04E-02 0.11 NP_057175 EIF3L 
Serine/threonine-protein phosphatase 
2A 65 kDa* 
1.87 1.07E-02 0.49 NP_055040 PPP2R1A 
Stress-induced-phosphoprotein 1 1.86 1.90E-02 0.09 NP_006810 STIP1 
Arginine-tRNA ligase, cytoplasmic 1.82 2.45E-02 0.13 NP_002878 RARS 
T-complex protein 1  1.80 4.39E-02 0.34 NP_036205 CCT5 
Elongation factor 2* 1.78 4.27E-02 0.98 NP_001952 EEF2 
Coatomer*  1.78 2.60E-02 0.03 NP_001646 ARCN1 
T-complex protein 1* 1.75 4.09E-02 0.13 NP_005989 CCT3 
Heterogeneous nuclear 
ribonucleoprotein K* 
1.71 4.37E-03 0.09 NP_112553 HNRNPK 
Zinc finger protein 292* 1.71 1.06E-02 0.13 NP_055836 ZNF292 
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Death-inducer obliterator 1 1.70 4.62E-02 0.28 NP_149072 DIDO1 
Mitotic spindle assembly checkpoint 
protein MAD1* 
1.69 1.42E-03 0.04 NP_003541 MAD1L1 
Afadin* 1.68 6.24E-04 0.03 NP_00103508
9 
MLLT4 
Connector enhancer of kinase 
suppressor of ras 2 
1.62 2.53E-02 0.22 NP_055742 CNKSR2 
Protein Shroom 4* 1.62 2.28E-02 0.21 NP_065768 SHROOM4 
60S ribosomal protein L9* 1.61 3.80E-02 0.26 NP_000652 RPL9 
Fez family zinc finger protein 1* 1.61 4.65E-02 0.28 NP_00101978
4 
FEZF1 
Poly [ADP-ribose] polymerase 4 1.58 1.11E-02 0.13 NP_006428 PARP4 
Glycogen phosphorylase, muscle 
form 
1.57 3.92E-04 0.02 NP_00115818
8 
PYGM 
Peroxisome proliferator-activated 
receptor gamma coactivator-related 
protein 1* 
1.54 8.25E-03 0.12 NP_055877 PPRC1 
Nuclear pore complex protein 
Nup98-Nup96* 
1.54 5.19E-04 0.02 NP_624358 NUP98 
TBC1 domain family member 2A* 1.53 6.99E-04 0.03 NP_060891 TBC1D2 
Transcriptional regulator ATRX* 1.52 6.45E-03 0.11 NP_000480 ATRX 
Tryptophan-tRNA ligase, 
cytoplasmic 
1.52 1.94E-02 0.19 NP_004175 WARS 
Fermitin family homolog 2 1.52 1.49E-02 0.16 NP_006823 FERMT2 
Thioredoxin 1.52 2.17E-02 0.20 NP_003320 TXN 
Lipid phosphate phosphatase-related 
protein type 4* 
1.51 6.02E-03 0.11 NP_055654 LPPR4 
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Table S2: Pathway analysis of proteins listed in Table S1. (a) Top networks, (b) molecular and cellular 
functions, The functional protein association network analysis was carried out with STRING version 
10.0 and Ingenuity Pathway Analysis software version 01-07 and gave consistent functional 
classifications of the proteins of interest as presented in (a-e).  
(a) Top Networks (IPA) 
ID Associated Network Functions                                                        Score 
Cellular Assembly and Organization, Post-Translational Modification, Protein Folding  62 
Cancer, Gastrointestinal Disease, Organismal Injury and Abnormalities 28 
Cancer, Gastrointestinal Disease, Hepatic System Disease  28 
Developmental Disorder, Hereditary Disorder, Metabolic Disease  25 
DNA Replication, Recombination, and Repair, Energy Production, Nucleic Acid 
Metabolism  
8 
 
(b) Molecular and cellular functions (IPA) 
Name                     p-value                                         #Molecules 
 
Cellular Assembly and Organization 4.86E-02 - 4.13E-05  
 
31 
Cellular Function and Maintenance 4.84E-02 - 4.13E-05  
 
20 
Cell Morphology 4.86E-02 - 7.43E-05  17 
Post-Translational Modification            4.40E-02 - 1.71E-05 8 
 
Protein Folding 4.69E-05 - 1.71E-05  5 
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